Tacalcitol
Based on 3 publication(s) in Google Scholar
Tacalcitol (1,24(R)-Dihydroxyvitamin D3; 1.alpha.,24R-Dihydroxyvitamin D3) can promote normal bone growth by regulating calcium ions. Tacalcitol inhibits cancer cell proliferation and migration. Tacalcitol can be used in the research of inflammation, cancer, and skin diseases.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.71%
- CAS No.: 57333-96-7
- 화학식: C27H44O3
- 분자량:416.64
-
보관:
4°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-10001
CalcipotriolVitamin D3 Analog -
HY-50919
ParicalcitolVitamin D Receptor Agonist -
HY-32348
DoxercalciferolVD/VDR Activator -
HY-32339
MaxacalcitolVDR Agonist -
HY-32343
SecalciferolVitamin D Metabolite -
HY-15310
IvermectinAnti-parasite Agent -
HY-15398
Vitamin D3Vitamin -
HY-A0245
DihydrotachysterolVitamin D Analog -
HY-32351
CalcifediolVDR Ligand -
HY-10002
CalcitriolVDR Agonist -
HY-15398R
Vitamin D3 (Standard)Vitamin -
HY-10003
AlfacalcidolVDR Activator
Publications Citing Use of MedChemExpress (MCE) Tacalcitol
More
Biological Activity
제품 설명
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HaCaT | IC50 |
2.07 μM
Compound: Tacalcitol
|
Cytotoxicity against human HaCaT cells after 48 hrs by MTT assay
Cytotoxicity against human HaCaT cells after 48 hrs by MTT assay
|
[PMID: 24099996] |
| HL-60 | EC50 |
7.05 nM
Compound: Tacalcitol
|
Agonist activity at VDR in human HL60 cells assessed as induction of cell differentiation after 96 hrs by NBT reduction assay
Agonist activity at VDR in human HL60 cells assessed as induction of cell differentiation after 96 hrs by NBT reduction assay
|
[PMID: 24099996] |
| MCF7 | IC50 |
0.057 μM
Compound: Tacalcitol
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 24099996] |
In Vitro
Tacalcitol (0.1-100 μM, 24 h) inhibits synthesis of both IL-6 and IL-8 in cultures derived from nasal polyps in dose-dependent manner[1].
Tacalcitol (10-4-1 μM, 48 h or one week) induces cell differentiation in normal human keratinocytes. Tacalcitol inhibits the growth of normal and psoriatic human keratinocytes[2][3].
Tacalcitol (0-1 μM, 48 h) inhibits DNA synthesis in normal human keratinocytes[3].
Tacalcitol (0.001-10 μM, 6 days) strongly reduces proliferation of human glioblastoma[4].
Tacalcitol (10 μM, 41 h) inhibits human glioblastoma migration[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:normal human keratinocytes
-
Concentration:10-10, 10-9, 10-8, 10-7, 10-6 M
-
Incubation Time:one week
-
Result:Significantly inhibited the growth of human keratinocytes at concentrations higher than 10-8 M.
The growth of keratinocytes was 65% inhibited by 10-8 M and 90% inhibited by 10-7 M
-
Cell Line:T98G cells
-
Concentration:0.001, 0.01, 0.1, 1, 10 μM
-
Incubation Time:6 days
-
Result:Treatment for 6 days resulted in a significant, dose-dependent inhibitory effect on cell viability/growth.
Treatment of cells for less than 6 days did not influence cell viability/growth.
-
Cell Line:T98G cells
-
Concentration:10 μM
-
Incubation Time:41 h (pre-treated for 24 h, then cells were scraped and monitore for 17 h)
-
Result:Reduced the migration rate.
After 17 hr, the wound closure of control cells was about 60%, while treated cells had a wound closure of about 35-45%.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female SKH1 (hr/hr) hairless mice (7-8 weeks old, Phorbol 12-myristate 13-acetate (HY-18739) (12-Otetradecanoylphorbol 13-acetate (TPA)) was topically applied to 6 cm2 area of the dorsal skin to induce cutaneous inflammation)[5]
-
Dosage:0.2, 2, 20 μg/g
-
Administration:Applied to the cutaneous inflammation area
-
Result:Significantly inhibited TPA-induced cutaneous inflammation, histopathologically.
The effect of 20 μg/g on cutaneous inflammation was much stronger than that of 2 μg/g.
20 μg/g also significantly inhibited TPA-induced myeloperoxidase (MPO) activity.
The effect on epidermal proliferation was significant at the doses of 2 μg/g and 20 μg/g, and that on epidermal differentiation was significant at the doses of 0.2 μg/g or more.
- BrdU Incorporation Assay
- Cell migration
- Somatic Cell Culture
- CFSE Dye Dilution Proliferation Assay
- Dye-dilution cell tracking and proliferation staining
- CCK-8/WST-8 Cell Proliferation Assay
- Protocol for Cell Cycle
- Cell Counting-Based Growth Curve Assay
- Research Protocol for Inflammation-related Diseases
- Colony Formation (Clonogenic) Assay
- Cell Viability Determination by MTT Colorimetric Assay
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Ki-67 Immunostaining Proliferation Assay
- PCNA Immunodetection Proliferation Assay
- Protocol for Cell Counting and Cell Density Analysis
- MTT Cell Proliferation Assay
Chemical Information
-
CAS No. 57333-96-7
-
Appearance Solid
-
분자량 416.64
-
화학식 C27H44O3
-
Color White to off-white
-
SMILES
C=C1[C@H](C[C@@H](C/C1=C/C=C2[C@]3([C@@](C)([C@H](CC3)[C@@H](CC[C@H](C(C)C)O)C)CCC/2)[H])O)O
-
Synonyms
1,24(R)-Dihydroxyvitamin D3; 1.alpha.,24R-Dihydroxyvitamin D3
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Virol Sin
Antiviral activity of vitamin D derivatives against severe fever with thrombocytopenia syndrome virus in vitro and in vivo. [Abstract]2024 Oct;39(5):802-811. PMID: 39168248 -
FEBS Open Bio
Vitamin D3 suppresses the cholesterol homeostasis pathway in patient-derived glioma cell lines. [Abstract]2023 Sep;13(9):1789-1806. PMID: 37489660 -
용액&용해도
In Vitro:
DMSO : ≥ 100 mg/mL (240.02 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.75 mg/mL (6.60 mM); Clear solution
This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.75 mg/mL (6.60 mM); Clear solution
This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (282 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
Handling Instructions (2659 KB)
References
[1]. Rostkowska-Nadolska B, et al. Vitamin D derivatives: calcitriol and tacalcitol inhibits interleukin-6 and interleukin-8 expression in human nasal polyp fibroblast cultures. Adv Med Sci. 2010;55(1):86-92. [Content Brief]
[2]. Kobayashi T, et al. 1 alpha,24R-dihydroxyvitamin D3 has an ability comparable to that of 1 alpha,25-dihydroxyvitamin D3 to induce keratinocyte differentiation. J Dermatol. 1990 Nov;17(11):707-9. [Content Brief]
[3]. Matsumoto K, et al. K. Effect of 1,24R-dihydroxyvitamin D3 on the growth of human keratinocytes. J Dermatol. 1990 Feb;17(2):97-103. [Content Brief]
[4]. Emanuelsson I, et al. Vitamin D Analogues Tacalcitol and Calcipotriol Inhibit Proliferation and Migration of T98G Human Glioblastoma Cells. Basic Clin Pharmacol Toxicol. 2018 Aug;123(2):130-136. [Content Brief]
[5]. Sato H, et al. Pharmacological profiles of high-concentration (20 microg/g) tacalcitol ointment: effects on cutaneous inflammation, epidermal proliferation, and differentiation in mice. J Dermatol. 2003 Jul;30(7):510-24. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4002 mL | 12.0008 mL | 24.0015 mL | 60.0038 mL |
| 5 mM | 0.4800 mL | 2.4002 mL | 4.8003 mL | 12.0008 mL | |
| 10 mM | 0.2400 mL | 1.2001 mL | 2.4002 mL | 6.0004 mL | |
| 15 mM | 0.1600 mL | 0.8001 mL | 1.6001 mL | 4.0003 mL | |
| 20 mM | 0.1200 mL | 0.6000 mL | 1.2001 mL | 3.0002 mL | |
| 25 mM | 0.0960 mL | 0.4800 mL | 0.9601 mL | 2.4002 mL | |
| 30 mM | 0.0800 mL | 0.4000 mL | 0.8001 mL | 2.0001 mL | |
| 40 mM | 0.0600 mL | 0.3000 mL | 0.6000 mL | 1.5001 mL | |
| 50 mM | 0.0480 mL | 0.2400 mL | 0.4800 mL | 1.2001 mL | |
| 60 mM | 0.0400 mL | 0.2000 mL | 0.4000 mL | 1.0001 mL | |
| 80 mM | 0.0300 mL | 0.1500 mL | 0.3000 mL | 0.7500 mL | |
| 100 mM | 0.0240 mL | 0.1200 mL | 0.2400 mL | 0.6000 mL |
Tacalcitol Related Classifications
HY-32337 Related Classifications
Powered by Bioz